1. Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. (12th June 2019) Authors: Ghia, P.; Pluta, A.; Wach, M.; Lysak, D.; Kozak, T.; Simkovic, M.; Kaplan, P.; Kraychok, I.; Illes, A.; De La Serna, J.; Dolan, S.; Campbell, P.; Musuraca, G.; Jacob, A.; Avery, E.J.; Lee, J.H.; Chen, T.; Liang, W.; Patel, P.; Jurczak, W. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Analyzing the Effect of Intensive and Low-Input Agrotechnical Support for the Physiological, Phenometric, and Yield Parameters of Different Maize Hybrids Using Multivariate Statistical Methods. (18th February 2021) Authors: Illes, A.; Bojtor, C.; Szeles, A.; Mousavi, S. M. N.; Toth, B.; Nagy, J. Other Names: Popovic Vera Academic Editor. Journal: International journal of agronomy Issue: Volume 2021(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effects of pituitary adenylate cyclase activating polypeptide on small intestinal INT 407 cells. (October 2017) Authors: Illes, A.; Opper, B.; Reglodi, D.; Kerenyi, M.; Czetany, P.; Boronkai, A.; Schafer, E.; Toth, G.; Fabian, E.; Horvath, G. Journal: Neuropeptides Issue: Volume 65(2017) Page Start: 106 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECITABINE IN AML PATIENTS. (23rd June 2022) Authors: Geissler, K.; Koristek, Z.; Bernal del Castillo, T.; Novák, J.; Rodriguez Macias, G.; Metzelder, S. K.; Illes, A.; Nagy, A.; Mayer, J.; Arnan, M.; Keating, M.-M.; Krauter, J.; Lunghi, M.; Stefano Fracchiolla, N.; Platzbecker, U.; Santini, V.; Sano, Y.; Oganesian, A.; Keer, H.; Lübbert, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP. (23rd June 2022) Authors: Ghia, P.; Pluta, A.; Wach, M.; Lysak, D.; Simkovic, M.; Kriachok, I.; Illes, A.; de la Serna, J.; Dolan, S.; Campbell, P.; Musuraca, G.; Jacob, A.; Avery, E.; Lee, J. H.; Usenko, G.; Wang, M. H.; Yu, T.; Jurczak, W. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 566 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY. (June 2017) Authors: Sehn, L.H.; Oestergaard, M.Z.; Trněný, M.; Bosi, A.; Egyed, M.; Illes, A.; Nakamae, H.; Opat, S.; Topp, M.; Zaja, F.; Fingerle‐Rowson, G.; Lei, G.; Nielsen, T.; Punnoose, E.A.; Rahman, M.; Ray, J.; Zhang, L.; Martelli, M.; Vitolo, U. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. S196: ROPEGINTERFERON ALFA-2B ACHIEVES PATIENT-SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD-PV/CONTINUATION-PV STUDIES. (23rd June 2022) Authors: Gisslinger, H.; Klade, C.; Georgiev, P.; Krochmalczyk, D.; Gercheva-Kyuchukova, L.; Egyed, M.; Dulicek, P.; Illes, A.; Pylypenko, H.; Sivcheva, L.; Mayer, J.; Yablokova, V.; Empson, V.; Krejcy, K.; Hasselbalch, H.; Kralovics, R.; Kiladjian, J.-J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗